ALTx Therapeutics

ALTx Therapeutics is a UK-based biotechnology startup focused on the discovery and development of first-in-class precision oncology medicines. The company specifically targets the Alternative Lengthening of Telomeres (ALT) pathway, a unique survival mechanism that allows cells in up to 15% of all cancers to achieve cellular immortality. By developing novel inhibitors for this cancer-specific biological process, ALTx aims to provide highly targeted treatments for patients suffering from aggressive tumors, including rare, pediatric, and brain cancers that currently have limited therapeutic options.

The company was spun out of the Francis Crick Institute and is built upon the foundational discoveries of its scientific founder, Simon Boulton, a globally recognized expert in DNA damage repair and telomere maintenance. Initially incorporated under the Slingshot accelerator umbrella, ALTx Therapeutics officially launched in February 2026 with a £12.55 million seed funding round. This financing was backed by leading life sciences investor Syncona, alongside the Francis Crick Institute and Cancer Research Horizons, to provide the necessary infrastructure to transition academic breakthroughs into tangible therapies.

Currently operating as a flagship venture within Syncona’s Slingshot platform, ALTx Therapeutics is rapidly advancing its pipeline of novel drug targets from pre-clinical research toward clinical readiness. The firm’s overarching mission is to leverage fundamental discovery science to strip aggressive tumors of their immortality mechanisms, ultimately delivering life-changing clinical outcomes and addressing critical unmet needs within the modern oncology landscape.

Keywords: biotechnology, oncology, precision medicine, therapeutics, cancer research, telomeres, drug discovery, spinout, DNA repair, targeted therapy.